Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas.

Trial Profile

Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Everolimus (Primary) ; Octreotide (Primary)
  • Indications Meningioma
  • Focus Therapeutic Use
  • Acronyms CEVOREM
  • Most Recent Events

    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Status changed to active, no longer recruiting as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 13 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top